Skip to content

News & Events

Academic GI Cancer Consortium (AGICC)

AGICC Investigators Meeting at ASCO 2012
Dr. Lawrence Leichman, AGICC Medical Director, will lead an Investigators’ Meeting – June 2, 2012 (11:30am – 1:30 pm) that includes some of the country's premier GI cancer experts. The meeting agenda will feature updates and protocol discussions on current studies, as well as presentations by companies collaborating with AGICC on clinical trials.
AGICC’s Medical Director, Dr. Lawrence Leichman to Present Poster at ASCO 2012 Meeting
Larry Leichman, MD (AGICC Medical Director) and Steve Cohen, MD (PI at Fox Chase Cancer Center) were notified on April 9th that the OSI abstract submitted to ASCO 2012 was accepted as a poster and is scheduled for presentation Monday, June 4th, 8AM-12 noon.
CORE Science Solutions, LLC. to Exhibit at 2012 ASCO and Host Meet and Greet Reception
CORE Science Solutions (CSS) Consortia, the Academic Gastrointestinal Cancer Consortium (AGICC) and Academic Myeloma Consortium (AMyC) will have a presence at the 2012 ASCO meeting June 1-4 in Chicago, IL.
AGICC to Exhibit at GI ASCO and Host Meet and Greet Reception
The Aptium Oncology GI Cancer Consortium (AGICC) will have a presence at the 2011 Gastrointestinal Cancers Symposium, 20-22, 2011 at The Moscone West Building in San Francisco. The symposium, also known as the GI ASCO, will feature more than 600 abstracts on the latest research in gastrointestinal cancers.
CRITERIUM, Inc. CRO Announces New Acquisition – Former Aptium Oncology Cancer Consortium Finds a New Home
Criterium, Inc., a full-service, global CRO, is pleased to announce the acquisition of the former Aptium Oncology’s CORE Science Solutions (CSS) Cancer Consortium Groups consisting of AGICC and AMyC as the newest members of Criterium’s Pharma services companies. Criterium is proud to include AGICC and AMyC, two academic cancer research consortia in its family of companies. Important and well-known institutions and investigators are actively collaborating as part of the consortia.